ArticleFrontiers in public health2026
Clinical burden, disease progression, and management strategies in chronic hepatitis B: implications for public health practice.
Article in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic hepatitis B (CHB) is one of the most significant global public health issues because it is progressive and has long-term complications, with gaps in real-world management. Longitudinal cohort evidence is required to guide effective disease control strategies. Objective: This study aimed to evaluate the clinical burden, disease progression, and management strategies in patients with CHB and to identify factors influencing progression and treatment outcomes in a real-world setting. Methods: The study design was a retrospective longitudinal cohort study conducted at a tertiary-care academic referral centre between January 2020 and December 2025. A total of 520 patients were analysed, all of whom were confirmed to have CHB and followed longitudinally through routine clinical care for a mean duration of 4.1 years. Assessment was made on clinical burden, disease progression and management strategies. Kaplan-Meier analyses were used to determine progression-free survival, and multivariable Cox proportional hazards regression was used to determine independent predictors of disease progression. Findings: 21.5% of patients in the baseline group were found to have significant fibrosis, and 9.8% of the patients had cirrhosis. Follow-up discovered disease evolution in 22.3%, including cirrhosis (11.9%), hepatocellular carcinoma (6.9%), and liver death (5.4%). 46.2% of the patients received antiviral therapy, which was associated with a high rate of progression-free survival. Older age, high levels of HBV DNA, baseline fibrosis, ALT elevation and diabetes mellitus were all independent predictors of disease progression, and antiviral therapy had a very strong protective effect (adjusted HR 0.52, 95% CI 0.36-0.75). It is important to note that almost 20% of eligible patients were not treated, and unstable monitoring was associated with poor clinical outcomes. Conclusion: CHB is associated with a significant clinical and healthcare burden. Antiviral interventions and regular observation in the early stages of the disease can greatly slow disease progression, and it is therefore crucial to enhance population health interventions to ensure a smooth transition between the guidelines applied and actual practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.